Press release
Limb Girdle Muscular Dystrophy Pipeline 2025: MOA, ROA, and Clinical Trial Insights Explored by DelveInsight | Catabasis Pharma, Sarepta Therapeutics, Strykagen, Sarepta Therapeutics, aTyr Pharma
"Limb Girdle Muscular Dystrophy Pipeline Insight, 2025 [https://www.delveinsight.com/report-store/limb-girdle-muscular-dystrophy-lgmd-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]" report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Limb Girdle Muscular Dystrophy Market.
The Limb Girdle Muscular Dystrophy Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.
Some of the key takeaways from the Limb Girdle Muscular Dystrophy Pipeline Report:
*
Companies across the globe are diligently working toward developing novel Limb Girdle Muscular Dystrophy treatment therapies with a considerable amount of success over the years. Limb Girdle Muscular Dystrophy Key players such as - Catabasis Pharmaceuticals, Sarepta Therapeutics, Strykagen, Sarepta Therapeutics, aTyr Pharma, ML Bio Solutions, and others, are developing therapies for the Limb Girdle Muscular Dystrophy treatment
*
Limb Girdle Muscular Dystrophy Emerging therapies such as - CAT-1004, SRP-9005, Stryka 516s, MYO 102, SRP-9003, ATYR1940, BBP-418, and others are expected to have a significant impact on the Limb Girdle Muscular Dystrophy market in the coming years.
*
In June 2025, Sarepta Therapeutics has been granted platform technology designation by the FDA for the rAAVrh74 viral vector used in bidridistrogene xeboparvovec (SRP-9003). This investigational gene therapy, which utilizes an adeno-associated virus (AAV) vector, is being developed for the treatment of limb-girdle muscular dystrophy Type 2E (LGMD2E/R4), also known as beta sarcoglycanopathy.
*
In March 2025, AskBio Inc., a gene therapy company fully owned and independently operated by Bayer AG, has announced the progression of its Phase 1/2 LION-CS101 clinical trial evaluating the investigational gene therapy AB-1003 for patients with limb-girdle muscular dystrophy type 2I/R9 (LGMD2I/R9). The trial has moved forward with the dosing of the first participant in the second cohort. This advancement follows a safety review by an independent Data Safety Monitoring Board (DSMB), which reviewed recruitment and safety data from the first cohort and concluded it was safe to proceed. DSMBs are expert panels that assess clinical trial data to evaluate safety, risk-benefit profiles, and any unexpected adverse effects.
Limb Girdle Muscular Dystrophy Overview
Limb-girdle muscular dystrophy (LGMD) refers to a group of inherited muscle disorders characterized by progressive weakness and wasting of the muscles around the hips and shoulders, known as the limb-girdle muscles. There are several subtypes of LGMD, each caused by mutations in different genes that play a role in muscle structure and function.
Get a Free Sample PDF Report to know more about Limb Girdle Muscular Dystrophy Pipeline Assessment- https://www.delveinsight.com/sample-request/limb-girdle-muscular-dystrophy-lgmd-pipeline-insight [https://www.delveinsight.com/sample-request/limb-girdle-muscular-dystrophy-lgmd-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]
Emerging Limb Girdle Muscular Dystrophy Drugs Under Different Phases of Clinical Development Include:
*
CAT-1004: Catabasis Pharmaceuticals
*
SRP-9005: Sarepta Therapeutics
*
Stryka 516s: Strykagen
*
MYO 102: Sarepta Therapeutics
*
SRP-9003: Sarepta Therapeutics
*
ATYR1940: aTyr Pharma
*
BBP-418: ML Bio Solutions
Limb Girdle Muscular Dystrophy Pipeline Therapeutics Assessment
*
Limb Girdle Muscular Dystrophy Assessment by Product Type
*
Limb Girdle Muscular Dystrophy By Stage and Product Type
*
Limb Girdle Muscular Dystrophy Assessment by Route of Administration
*
Limb Girdle Muscular Dystrophy By Stage and Route of Administration
*
Limb Girdle Muscular Dystrophy Assessment by Molecule Type
*
Limb Girdle Muscular Dystrophy by Stage and Molecule Type
DelveInsight's Limb Girdle Muscular Dystrophy Report covers around 25+ products under different phases of clinical development like
*
Late-stage products (Phase III)
*
Mid-stage products (Phase II)
*
Early-stage product (Phase I)
*
Pre-clinical and Discovery stage candidates
*
Discontinued & Inactive candidates
*
Route of Administration
Download Sample PDF Report to know more about Limb Girdle Muscular Dystrophy drugs and therapies [https://www.delveinsight.com/report-store/limb-girdle-muscular-dystrophy-lgmd-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]
Limb Girdle Muscular Dystrophy Pipeline Analysis:
The Limb Girdle Muscular Dystrophy pipeline report provides insights into
*
The report provides detailed insights about companies that are developing therapies for the Limb Girdle Muscular Dystrophy treatment with aggregate therapies developed by each company for the same.
*
It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Limb Girdle Muscular Dystrophy Treatment.
*
Limb Girdle Muscular Dystrophy key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
*
Limb Girdle Muscular Dystrophy Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
*
Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Limb Girdle Muscular Dystrophy market.
The report is built using data and information traced from the researcher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.
Further Limb Girdle Muscular Dystrophy product details are provided in the report. Download the Limb Girdle Muscular Dystrophy pipeline report to learn more about the emerging Limb Girdle Muscular Dystrophy therapies [https://www.delveinsight.com/report-store/limb-girdle-muscular-dystrophy-lgmd-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]
Limb Girdle Muscular Dystrophy Pipeline Market Drivers
*
Increasing awareness about available treatment options
*
A better understanding of disease pathogenesis
Limb Girdle Muscular Dystrophy Pipeline Market Barriers
*
No cure exists for any form of Limb Girdle Muscular Dystrophy
*
Lack of proper Genetic Counselling, which is to be given to individuals and their families.
Scope of Limb Girdle Muscular Dystrophy Pipeline Drug Insight
*
Coverage: Global
*
Key Limb Girdle Muscular Dystrophy Companies: Catabasis Pharmaceuticals, Sarepta Therapeutics, Strykagen, Sarepta Therapeutics, aTyr Pharma, ML Bio Solutions, and others
*
Key Limb Girdle Muscular Dystrophy Therapies: CAT-1004, SRP-9005, Stryka 516s, MYO 102, SRP-9003, ATYR1940, BBP-418, and others
*
Limb Girdle Muscular Dystrophy Therapeutic Assessment: Limb Girdle Muscular Dystrophy current marketed and Limb Girdle Muscular Dystrophy emerging therapies
*
Limb Girdle Muscular Dystrophy Market Dynamics: Limb Girdle Muscular Dystrophy market drivers and Limb Girdle Muscular Dystrophy market barriers
Request for Sample PDF Report for Limb Girdle Muscular Dystrophy Pipeline Assessment and clinical trials [https://www.delveinsight.com/report-store/limb-girdle-muscular-dystrophy-lgmd-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]
Table of Contents
1
Limb Girdle Muscular Dystrophy Report Introduction
2
Limb Girdle Muscular Dystrophy Executive Summary
3
Limb Girdle Muscular Dystrophy Overview
4
Limb Girdle Muscular Dystrophy- Analytical Perspective In-depth Commercial Assessment
5
Limb Girdle Muscular Dystrophy Pipeline Therapeutics
6
Limb Girdle Muscular Dystrophy Late Stage Products (Phase II/III)
7
Limb Girdle Muscular Dystrophy Mid Stage Products (Phase II)
8
Limb Girdle Muscular Dystrophy Early Stage Products (Phase I)
9
Limb Girdle Muscular Dystrophy Preclinical Stage Products
10
Limb Girdle Muscular Dystrophy Therapeutics Assessment
11
Limb Girdle Muscular Dystrophy Inactive Products
12
Company-University Collaborations (Licensing/Partnering) Analysis
13
Limb Girdle Muscular Dystrophy Key Companies
14
Limb Girdle Muscular Dystrophy Key Products
15
Limb Girdle Muscular Dystrophy Unmet Needs
16
Limb Girdle Muscular Dystrophy Market Drivers and Barriers
17
Limb Girdle Muscular Dystrophy Future Perspectives and Conclusion
18
Limb Girdle Muscular Dystrophy Analyst Views
19
Appendix
20
About DelveInsight
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.
Media Contact
Company Name: DelveInsight
Contact Person: Gaurav Bora
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=limb-girdle-muscular-dystrophy-pipeline-2025-moa-roa-and-clinical-trial-insights-explored-by-delveinsight-catabasis-pharma-sarepta-therapeutics-strykagen-sarepta-therapeutics-atyr-pharma]
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/
Legal Disclaimer: Information contained on this page is provided by an independent third-party content provider. ABNewswire makes no warranties or responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you are affiliated with this article or have any complaints or copyright issues related to this article and would like it to be removed, please contact retract@swscontact.com
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Limb Girdle Muscular Dystrophy Pipeline 2025: MOA, ROA, and Clinical Trial Insights Explored by DelveInsight | Catabasis Pharma, Sarepta Therapeutics, Strykagen, Sarepta Therapeutics, aTyr Pharma here
News-ID: 4135863 • Views: …
More Releases from ABNewswire
Miller & Smith Announces Retirement of Longtime Vice President of Land Developme …
Miller & Smith announces the retirement of Robert Spalding, Vice President of Land Development, following nearly 20 years of leadership at the company and over 40 years of influence in urban planning across both public and private sectors. Since joining Miller & Smith in 2005, Spalding has shaped transformative communities like Tallyn Ridge in Frederick County, as well as Centerpark, Gallery Park, and Woodcrest in Montgomery County.
McLean, VA - Aug…
Atypical Teratoid Rhabdoid Tumors Pipeline 2025: Detailed Clinical Trials and FD …
Atypical Teratoid Rhabdoid Tumors pipeline constitutes 6+ key companies continuously working towards developing 6+ Atypical Teratoid Rhabdoid Tumors treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight.
"Atypical Teratoid Rhabdoid Tumors Pipeline Insight, 2025 [https://www.delveinsight.com/report-store/atypical-teratoid-rhabdoid-tumors-atrt-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]" report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Atypical Teratoid Rhabdoid Tumors Market.
The Atypical Teratoid Rhabdoid Tumors Pipeline report…
Plumbers at Foster Plumbing & Heating Deliver Fast Solutions for Frozen Pipe Eme …
When storms hit, plumbing systems are often among the first to suffer. Heavy rain can overwhelm drainage systems, back up sewer lines, or even lead to basement flooding.
Storm-Ready Solutions Backed by Trusted Local Plumbing Experts
Severe storms in Richmond, VA have led to more than just fallen trees and power outages-residents are also facing increased demand for fast, affordable plumbing support. While many have searched for Cheap Plumbers Near Me [https://www.google.com/search?Cheap+Plumbers+Near+Me&kgmid=/g/11jh2f3tzx]…
Foster Plumbing & Heating Responds to Storm Season with Surge in Generator Insta …
Unreliable electrical service during major storms can lead to more than just inconvenience. Power loss affects heating and cooling systems, medical equipment, security devices, refrigeration, and more.
Increased Demand Reflects Growing Concern Over Power Reliability
As storm season intensifies across Central Virginia, homeowners and businesses are taking proactive steps to avoid power outages and the disruptions that follow. One of the most sought-after solutions is generator installation [https://fosterpandh.com/#:~:text=Professional%20Plumbing%20and-,Generator%20Services,-At%20Foster%20Plumbing], a service now seeing…
More Releases for Limb
Critical Limb Ischemia Pipeline: Advancing Regenerative Therapies and Novel Inte …
The treatment landscape for Critical Limb Ischemia (CLI), the most severe form of peripheral arterial disease, is evolving rapidly as the limitations of conventional revascularization and amputation drive demand for novel therapeutic approaches. Breakthroughs in angiogenesis, stem cell therapies, gene therapy, and immunomodulation are reshaping the future of CLI management, offering hope for tissue regeneration and improved limb salvage outcomes.
DelveInsight's "Critical Limb Ischemia - Pipeline Insight, 2025" provides an in-depth…
Limb Prosthetics Market Size And Trends
𝐔𝐒𝐀, 𝐍𝐞𝐰 𝐉𝐞𝐫𝐬𝐞𝐲- Limb Prosthetics Market is growing at a faster pace with substantial growth rates over the last few years and is estimated that the market will grow significantly in the forecasted period i.e. 2020 to 2027.
Limb Prosthetics Market Growth Driver
The limb prosthetics market is experiencing significant growth, driven by several key factors, including the rising prevalence of limb loss due to diabetes, vascular diseases, and traumatic injuries. As…
Pediatric Lower Limb Prosthetics Market
The "Pediatric Lower Limb Prosthetics Market" is expected to reach USD xx.x billion by 2031, indicating a compound annual growth rate (CAGR) of xx.x percent from 2024 to 2031. The market was valued at USD xx.x billion In 2023.
Growing Demand and Growth Potential in the Global Pediatric Lower Limb Prosthetics Market, 2024-2031
Verified Market Research's most recent report, "Pediatric Lower Limb Prosthetics Market: Global Industry Trends, Share, Size, Growth, Opportunity and…
Limb Prosthetics Market 2024 Strategic Assessment
In recent years, the global Limb Prosthetics Market has witnessed a dynamic shift, influenced by changing consumer preferences, technological advancements, and a growing emphasis on sustainability. The Research report on Limb Prosthetics Market presents a complete judgment of the market through strategic insights on future trends, growth factors, supplier landscape, demand landscape, Y-o-Y growth rate, CAGR, pricing analysis. It also provides and a lot of business matrices including Porters Five…
Lower Limb Rehabilitation Exoskeleton Robot | WALKBOT
The exoskeleton robotic rehabilitation devices made by WALKBOT provide robot-assisted gait training rehabilitation systems for musculoskeletal disabilities.
Walkbot Advanced solutions
The Walkbot, lower limb rehabilitation robot provides exciting customized 3-dimensional augmented reality exercise games so that their clients actually do not perceive the gait training as a form of therapy. Rather, they enjoy walking in interactive and ecologically natural or virtual environments as used by the software.
Game-Like Rehabilitation Training: Go World immerses…
Critical Limb Ischemia - Drug Pipeline Landscape, 2022
Critical limb ischemia is a serious form of peripheral arterial disease, or PAD where severe blockage in the arteries of the lower extremities (hands, feet and legs) occurs, which markedly reduces blood-flow. It results in severe pain and even skin ulcers or sores.
Peripheral artery disease causes chronic limb-threatening ischemia. Other causes of limb ischemia include embolisms, trauma and compartment syndrome.
The most common symptom of critical limb ischemia is ischemic…
